Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Our CEACAM5 CAR-T products and services are designed to help researchers and biopharmaceutical companies accelerate their development of innovative cancer immunotherapies. Please find the appropriate products you need.
CEACAM5, also known as carcinoembryonic antigen-related cell adhesion molecule 5, is a cell surface glycoprotein that plays a critical role in various human tumors, including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), breast cancer, and neuro-endocrine prostate cancer (NEPC). Overexpression of CEACAM5 has been associated with tumor differentiation, invasion, and metastasis in these cancers. Therapies targeting CEACAM5, such as CAR-T cells, have shown promising results in combating cancer cells expressing CEACAM5.
Fig.1 Expressions of CEACAM5 in different normal or tumor tissues.1
Associated Disease
Creative Biolabs has developed a variety of methods to confirm the expression of chimeric antigen receptors on engineered CART cells, such as flow cytometry, WB, etc. Flow cytometry is the more common approach, in which CAR target antigens are linked to fluorescent tags such as PE or APC for direct detection. This method is favored for its low background noise and high specificity for CAR proteins. In addition, universal detection using linker antibodies, or anti-mouse/human Fab antibodies provides an alternative method for CAR detection and quantification.
Phenotype testing of CAR-T cells serves as a crucial step in assessing the function of CART cells. This testing involves characterizing the expression of surface markers, and functional molecules on the engineered T cells. Creative Biolabs has launched comprehensive characterization testing for CAR-T cells to evaluate the presence of other surface markers associated with T cell activation, differentiation, exhaustion, memory formation, etc. This analysis will provide insights into the functionality and behavior of the CAR-T cells in vitro.
In vitro cytotoxicity assays are crucial during early CART development and optimization, which provide valuable insights into the mechanism of action, efficacy, and specificity of the treatment. Creative Biolabs provides sensitive cytotoxicity detections based on several approaches, including RTAC analysis, LDH detection, and flow cytometry.
Fig.2 In vitro cytotoxicity of anti-CEACAM5 CAR-T cells against different tumor cells at indicated E:T ratio.1
The choice of animal model for CART in vivo study is crucial and should reflect the intended clinical application of the therapy. Different models such as xenograft, humanized, syngeneic, and transgenic models can provide insights into various aspects of CAR-T cell therapy, including efficacy, toxicity, and specificity. For example, xenograft models involving immunocompromised mice injected with human tumor cells can be valuable for evaluating the antitumor activity of CAR-T cells. We offer a variety of animal models for customers to choose the appropriate model for CART in vivo experiments.
Fig.3 Schematic representation of Anti-CEACAM5 CAR-T in vivo experimental design.1
In vitro cytotoxicity assays are crucial during early CART development and optimization, which provide valuable insights into the mechanism of action, efficacy, and specificity of the treatment. Creative Biolabs provides one-stop in vivo study service with evaluation of multiple parameters such as tumor growth inhibition, tumor regression, cytokine release, and potential off-target effects on healthy tissues. By carefully monitoring these factors in relevant animal models, researchers can better understand the therapeutic potential and safety of CAR-T cell therapy before proceeding to clinical trials.
Fig.4 In vivo efficacy of anti-CEACAM5 CAR-T cells in the A549-CEACAM5 CDX models. (B) Tumor growth curve of CDX models with the CAR-T treatment. (C) Survival curve of CDX model with the CAR-T treatment.1
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-CQ0451 | Anti-CEACAM5 (161 (NCRC16)) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 161 (NCRC16) | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-SB-LX0164 | Anti-CEACAM5 (Altumomab) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | Altumomab | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| CAR-SB-LX0165 | Anti-CEACAM5 (32B10) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | 32B10 | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| CAR-SB-LX0166 | Anti-CEACAM5 (A5) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | A5 | Humanized | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| CAR-SB-LX0167 | Anti-CEACAM5 (CEA Il) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | CEA Il | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0622-ZP3300 | Anti-CEACAM5 h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-0622-ZP3472 | Anti-CEACAM5 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
| XS-0922-ZP896 | Anti-CEACAM5 (CB-P17) h(CD28-CD3ζ) CAR, pCDCAR1 | Mouse | CB-P17 | Rat | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0922-ZP1206 | Anti-CEACAM5 (CB-P17) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Mouse | CB-P17 | Rat | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0123-ZP526 | Anti-CEACAM5 (CB-P17) h(scFv-CD3ε) TRuC, pCDTRC1 | Mouse | CB-P17 | Rat | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP734 | Anti-CEACAM5 (MFE23) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | MFE23 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP828 | Anti-CEACAM5 (1G9) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 1G9 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP526 | Anti-CEACAM5 (CB-P17 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Mouse | CB-P17 | Rat | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP734 | Anti-CEACAM5 (MFE23 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | MFE23 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP828 | Anti-CEACAM5 (1G9 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 1G9 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0923-LX88 | Anti-hCEACAM5 (CD28-41BB-CD3ζ) CAR-duplex CTLA4 pCDCAR1 Vector | Human | X9X-57 | scFv-CD28-41BB-CD3ζ-duplex CTLA4 | Lentiviral vector | T cell | CAR-T |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
